Company intelligence / Profile preview

CAMP4 Therapeutics

Cambridge, Massachusetts, United Statescamp4tx.com ↗

Ownership: Public · CAMP
Employees: ~55
Development stage: Phase 1

Overview

The company’s lead candidate, CMP-CPS-001, is in a Phase 1 trial for urea cycle disorders with interim safety data showing favorable results in healthy volunteers. Preclinical data support the potential of their regulatory RNA-targeting approach to upregulate protein production in genetic diseases with insufficient protein levels. Additional programs are advancing toward IND-enabling studies.[6][8][9]

Therapeutic areas: NeurologyMetabolic Disorders
Modalities: Antisense oligonucleotides (ASOs)RNA-based therapeutics[2][8]
Industry: Biotech

Drug pipeline

5 assets

CMP-CPS-001

4 more assets in the full pipeline.

Request access →

Financials

Market cap: $92.2M
Total revenue: $1.8M
Enterprise value: $7.4M

Beyond the preview

Go deeper on CAMP4 Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CAMP4 Therapeutics.

Explore the full profile